A Trial of Lopinavir-Ritonavir in Covid-19

被引：0
|
作者：
Carmona-Bayonas, Alberto [1 ]
Jimenez-Fonseca, Paula [2 ]
Castanon, Eduardo [3 ]
机构：
[1] Hosp Univ Morales Meseguer, Murcia, Spain
[2] Hosp Univ Cent Asturias, Oviedo, Spain
[3] Clin Univ Navarra, Madrid, Spain
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [41] Lopinavir / ritonavir for COVID-19: A living systematic review
    Verdugo-Paiva, Francisca
    Izcovich, Ariel
    Ragusa, Martin
    Rada, Gabriel
    MEDWAVE, 2020, 20 (06):
  • [42] Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
    Jean Claude Alvarez
    Pierre Moine
    Benjamin Davido
    Isabelle Etting
    Djillali Annane
    Islam Amine Larabi
    Nicolas Simon
    European Journal of Clinical Pharmacology, 2021, 77 : 389 - 397
  • [43] Hair loss induced by lopinavir-ritonavir
    Borras-Blasco, Joaquin
    Belda, Alberto
    Rosique-Robles, Dolores
    Castera, Elvira
    Abad, Javier
    Amoros-Quiles, Isabel
    PHARMACOTHERAPY, 2007, 27 (08): : 1215 - 1218
  • [44] Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
    Baghaei, Parvaneh
    Dastan, Farzaneh
    Marjani, Majid
    Moniri, Afshin
    Abtahian, Zahra
    Ghadimi, Somayeh
    Valizadeh, Melika
    Heshmatnia, Jalal
    Mirenayat, Maryam Sadat
    Abedini, Atefeh
    Kiani, Arda
    Eslaminejad, Alireza
    Hashemian, Seyed MohammadReza
    Jamaati, Hamidreza
    Zali, Alireza
    Velayati, Ali Akbar
    Tabarsi, Payam
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92
  • [45] Lopinavir-ritonavir: A new protease inhibitor
    Mangum, EM
    Graham, KK
    PHARMACOTHERAPY, 2001, 21 (11): : 1352 - 1363
  • [46] SARS-CoV-2 viral dynamics and population pharmacokinetics of favipiravir in combination with lopinavir-ritonavir in patients with COVID-19
    Agyeman, Akosua A.
    Brown, Li-An K.
    Guerra-Assuncao, Jose A.
    Breuer, Judy
    Lowe, David M.
    Standing, Joseph F.
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 291 - 294
  • [47] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
  • [48] Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
    Zhu, Zhen
    Lu, Zhaohui
    Xu, Tianmin
    Chen, Cong
    Yang, Gang
    Zha, Tao
    Lu, Jianchun
    Xue, Yuan
    JOURNAL OF INFECTION, 2020, 81 (01) : E21 - E23
  • [49] Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
    Mazan, Paula
    Lesiak, Aleksandra
    Skibinska, Malgorzata
    Kamerys, Juliusz
    Czajkowski, Rafal
    Owczarek, Witold
    Narbutt, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 435 - 437
  • [50] Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients
    Chouchana, Laurent
    Boujaafar, Sana
    Gana, Ines
    Preta, Laure-Helene
    Regard, Lucile
    Legendre, Paul
    Azoulay, Celia
    Canoui, Etienne
    Zerbit, Jeremie
    Carlier, Nicolas
    Terrier, Benjamin
    Kerneis, Solen
    Batista, Rui
    Treluyer, Jean-Marc
    Zheng, Yi
    Benaboud, Sihem
    THERAPEUTIC DRUG MONITORING, 2021, 43 (01) : 131 - 135
12345